Clinical Trial Update: TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

View source ↗

Summary

This ClinicalTrials.gov update reports the completion of the TrinetX study on Hypereosinophilic Syndrome without an identifiable non-haematological secondary ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Snippet

Sponsor: AstraZeneca | Conditions: Hypereosinophilic Syndrome (HES) | Status: COMPLETED